SLC5A2 and diabetes mellitus: In an RCT study of three groups of insulin‐treated patients with diabetes, namely (i) continued intensified therapy, (ii) the addition of an SGLT2 inhibitor to a once‐daily basal insulin analog, and (iii) changes to the combination of basal insulin and GLP‐1 receptor agonists, glycemic control was similar, but the SGLT2 inhibitor and combination groups had their number of insulin units and hypoglycemia levels decreased by >50%.74